Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis

Abstract

The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having a therapeutic effect in subjects with a neurodegenerative disease and / or a motor neuron disease. In some embodiments, the disease is amyotrophic lateral sclerosis.

Description

technical field

[0001] The present disclosure relates to compositions and methods for ameliorating or treating at least one symptom of a neurodegenerative process or disease. Background technique

[0002] At any given time, as many as 30,000 Americans suffer from the almost always fatal amyotrophic lateral sclerosis (ALS). ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that attacks motor neurons in the brain and spinal cord and causes muscle weakness and atrophy. Early symptoms include loss of dexterity and gait. As the disease progresses, patients become paralyzed and require respiratory support. After diagnosis, the life expectancy of ALS patients is usually 3 to 5 years, and the leading cause of death is loss of respiratory function.

[0003] The etiology of ALS is only partially understood. Familial (inherited) cases account for only about 5%-10% of all ALS patients. In this subgroup of ALS patients, one in five carries the only ...

Images